

Molecular mechanisms of niacin-induced flushing



Zoltán Benyó, MD, PhD, DSc

*Institute of Translational Medicine,
Semmelweis University, Budapest*

Nicotinic acid (niacin, B₃ vitamin, antipellagra vitamin)

- **Physiological function:**
Vitamin (precursor for NAD⁺ and NADP⁺)
- **Required dose:** >15–20 mg/day in the diet
- **Required plasma level:** 100–400 nM
- **Nicotinamide is equivalent to nicotinic acid as a vitamin**
- **No side effects**
- **Pharmacological effects:**
Antidyslipidemic drug (LDL-C↓, TAG↓, HDL-C↑)
- **Required dose:** 500–2000 mg/day
- **Required plasma level:** 4–16 µM (peak concentrations: 50–300 µM)
- **Nicotinamide does not show the same pharmacological effects as nicotinic acid**
- **Side effects:** flush-reaction, gastrointestinal symptoms

Mediation of the pharmacological effects of nicotinic acid




Tunaru et al. Nat Med. 9:352-355, 2003

The flush-reaction




Measurement of nicotinic acid induced flushing in the mouse ear


Laser-Doppler scanner







Laser-Doppler monitor



Nicotinic acid ip.




Nicotinic acid- and acipimox-induced flushing response in the mouse ear and its desensitization




NA = nicotinic acid, APX = acipimox, both 200 mg/kg ip.

PUMA-G receptor deficiency abolishes the flushing response to nicotinic acid but not to prostaglandin D₂


A




B




C




D




E





Nicotinic acid →







Unchanged flushing response to nicotinic acid in endothelial NO synthase deficient mice







Diminished flushing response to nicotinic acid in cyclooxygenase-1 deficient mice





Prostaglandin D₂ induces flushing without development of tachyphylaxia



DP receptor deficiency abolishes the flushing response to PGD₂ but only partially reduces the effect of NA




The flush-reaction is mediated by DP, EP₂ and EP₄ receptors




PUMA-G receptor is expressed in immune cells of the skin

Northern blot







RT-PCR



BAT = brown adipose tissue; WT = PUMA-G^{+/+}; KO = PUMA-G^{-/-}

Transplantation of wild-type bone marrow to PUMA-G^{-/-} recipients restores the flushing response to nicotinic acid

RT-PCR




Identification of the immune-cell(s) mediating the flush reaction

Mast cells

Antigen presenting cells in the skin

- Macrophage
- Dendritic cell
- Langerhans cell



Flush-reaction in a mast cell deficient mouse



Toxin receptor-mediated conditional cell knockout (TRECK)




Conditional cell ablation using the human diphtheria toxin (DT) / DT receptor (DTR) system

A






DT = diphtheria toxin
HB-EGF = heparin-binding epidermal growth factor (human DT-B receptor)
EF-2 = elongation factor 2



Depletion of CD-11b⁺ macrophages does not influence the flush reaction






Depletion of CD-11c⁺ dendritic cells does not influence the flush reaction




Diminished flushing response after depletion of langerin⁺ epidermal Langerhans cells



Nicotinic acid induced, PUMA-G receptor mediated $[Ca^{2+}]_i$ -increase in epidermal Langerhans cells




PGE₂-synthase-1 is not expressed in epidermal Langerhans cells




PGE₂-synthase-2 is expressed in epidermal Langerhans cells





MHCII




mPGES-2




overlay



PGD_2 -synthase is expressed in epidermal Langerhans cells



Summary: mediation of the pharmacological effects of nicotinic acid



Tunaru et al. *Nat Med.* 9:352-355, 2003

Benyó et al. *J Clin Invest.* 115: 3634-3640, 2005
Benyó et al. *Mol. Pharmacol.* 70:1844-1849, 2006

Institute of Pharmacology, Ruprecht Karls University, Heidelberg:

***Jukka Kero, Andreas Gille, Sorin Tunaru, Marion Csiky,
Marie Suchánková, Alexandra Moers, Stefan Offermanns***

Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam:

Clare L. Bennett, Björn E. Clausen

Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Frankfurt am Main:

Rolf M. Nüsing

Institute of Medical Microbiology, University of Düsseldorf:

Klaus Pfeffer

Thanks for your attention!